Cancer Research

Patient using a mammography machine
#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Phase II trial #Phesi

Breast cancer most researched disease area for third year running

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The analysis of 65,749 recruiting clinical trials was conducted by data analytics company Phesi, as part of an annual global analysis of clinical… Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

Blood cells
#Blood cancer #Gene mutation #Oncology #University of Cambridge #Wellcome Sanger Institute

Study reveals how genetic mutations combine to cause cancer

UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease. Researchers from the Wellcome Sanger Institute,… Read More

#Cancer Research #News

Cytokine release syndrome
#Cancer treatment #Clinical trials #Haematology #Immunotherapy #Institute of Cancer Research #Poolbeg Pharma

Treatment potential for immunotherapy-induced CRS

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS).   POLB 001 demonstrated efficacy in reducing… Read More

#Cancer Research #News

#Cancer #Diagnostics #Drug discovery #Oncology #Precision medicine

Can liquid biopsies transform precision medicine?

Brett Swansiger, Chief Commercial Officer at ANGLE, discusses the importance of liquid biopsies in precision medicine trials for cancer.   Challenges in the oncology clinical trials space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027… Read More

#Cancer Research #Exclusive Content

Cancer Research
#Cancer research #Cancer Research Horizons #Precision medicine #Regulatory #Start-ups #Technology

Conversations from Cancer Research Horizons’ Innovation Summit 2023 

Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. DDW’s Megan Thomas spoke to a range of attendees.   Trends for cancer research  … Read More

#Cancer Research #Exclusive Content #Opinion #Regulatory

Breast cancer cell
#Breast cancer #Cancer research #Oncology #The Institute of Cancer Research

Discovery lights the way for new secondary breast cancer drugs

Using a novel approach, researchers from The Institute of Cancer Research, London have uncovered details of secondary breast cancer in the brain and spinal cord that may help with developing effective treatments. The study revealed for the first time that breast cancer leptomeningeal metastasis (BCLM) cells… Read More

#Cancer Research #News

Myeloma cells
#Blood cancer #CellCentric #Haematology #Myeloma #Oncology #Phase I trial

New class of drug shows promise in last line multiple myeloma

Data presented at the American Society for Hematology meeting (ASH) show a 70% response rate in last line multiple myeloma patients treated with CellCentric’s inobrodib in combination with pomalidomide (pom) and dexamethasone (dex). Inobrodib is the first in a new class of drug, which disrupts the… Read More

#Cancer Research #News

Blood cancer
#Acute Myeloid Leukaemia #Biologics #Blood cancer #CAR-T #University College London #ViroCell Biologics

UCL accelerates research of relapse in childhood blood cancer 

The University College London (UCL) has entered into a partnership with ViroCell Biologics to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).   Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of… Read More

#Cancer Research #News

Breast cancer research
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #Clinical trials #Oncology

The latest advances in breast cancer therapy

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including… Read More

#Cancer Research #News #Trending News

Colorectal cancer
#Bowel cancer #Cancer research #Cidara #ESMO #Immuno-oncology #Oncology #Preclinical development

Drug-Fc conjugates exhibit robust anti-tumour activity

A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We are thrilled to be presenting promising preclinical data on our novel multi-specific… Read More

#Cancer Research #News

CAR-T therapy
#Blood cancer #CAR-T #Haematology #Kite Pharma #Oncology #Real world data

Real-world evidence supports use of CAR-T therapies in blood cancers

Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7% in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). Axicabtagene ciloleucel was also associated with less than 5% grade ≥3 cytokine… Read More

#Cancer Research #News #Trending News

Colon cancer
#Bowel cancer #Cancer research #Chemotherapy-resistance #Oncology #University College London #Yale University

New discovery could make bowel cancer treatment more effective

Chemotherapy becomes less effective because healthy cells push cancer cells to grow more slowly, according to the findings of two studies from University College London (UCL) and Yale University. Bowel cancer kills over 900,000 people a year and is the second highest cause of cancer mortality… Read More

#Cancer Research #Editor's Choice #News

Natural killer cells
#Bispecific Antibodies #Cell therapy #Collaboration #NAYA Biosciences #Oncology #ONK Therapeutics

Partners explore NK cell therapy and bispecific antibodies combo

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted… Read More

#Business & Investment #Cancer Research #News

#Cancer research #Cancer Research Horizons #Cancer Research UK #Collaboration #Guardant Health #Precision medicine

CRUK and Guardant collaborate on precision cancer drugs

Cancer Research UK (CRUK), Cancer Research Horizons, and precision oncology company Guardant Health have launched a collaboration to advance cancer treatment. The agreement will enable the parties to discuss opportunities for collaboration to support the charity’s research and clinical development activities, focusing primarily on its clinical trials run by its… Read More

#Business & Investment #Cancer Research #News